Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network

Ludwig, H. (Heinz); Delforge, M. (M.); Facon, T. (Thierry); Einsele, H. (Hermann); Gay, F. (Francesca); Moreau, P. (Philippe); Avet-Loiseau, H. (Herve); Boccadoro, M. (Mario); Hajek, R. (R.); Mohty, M. (Mohamad); Cavo, M. (Michele); Dimopoulos, M.A. (Meletios A.); San-Miguel, J.F. (Jesús F.); Terpos, E. (Evangelos); Zweegman, S. (Sonja); Garderet, L. (Laurent); Mateos, M.V. (María Victoria); Cook, G. (Gordon); Leleu, X. (Xavier); Goldschmidt, H. (Hartmut); Jackson, G.H. (Graham H.); Kaiser, M. (Martin); Weisel, K. (Katja); Donk, N.W.C.J. (Niels W.C.J.) van de; Waage, A. (Anders); Beksac, M. (Meral); Mellqvist, U. (Ulf); Engelhardt, M. (Monika); Caers, J. (Jo); Driessen, C. (Cristoph); Bladé, J. (Joan); Sonneveld, P. (Pieter)

Registro completo de metadatos

Aparece en las colecciones:

DA - CIMA - Hemato-oncología - Epigenética - Artículos de Revista
DA - CUN - Hematología y Hemoterapia - Artículos de revista

Campo DC	Valor	Lengua/Idioma
dc.creator	Ludwig, H. (Heinz)	-
dc.creator	Delforge, M. (M.)	-
dc.creator	Facon, T. (Thierry)	-
dc.creator	Einsele, H. (Hermann)	-
dc.creator	Gay, F. (Francesca)	-
dc.creator	Moreau, P. (Philippe)	-
dc.creator	Avet-Loiseau, H. (Herve)	-
dc.creator	Boccadoro, M. (Mario)	-
dc.creator	Hajek, R. (R.)	-
dc.creator	Mohty, M. (Mohamad)	-
dc.creator	Cavo, M. (Michele)	-
dc.creator	Dimopoulos, M.A. (Meletios A.)	-
dc.creator	San-Miguel, J.F. (Jesús F.)	-
dc.creator	Terpos, E. (Evangelos)	-
dc.creator	Zweegman, S. (Sonja)	-
dc.creator	Garderet, L. (Laurent)	-
dc.creator	Mateos, M.V. (María Victoria)	-
dc.creator	Cook, G. (Gordon)	-
dc.creator	Leleu, X. (Xavier)	-
dc.creator	Goldschmidt, H. (Hartmut)	-
dc.creator	Jackson, G.H. (Graham H.)	-
dc.creator	Kaiser, M. (Martin)	-
dc.creator	Weisel, K. (Katja)	-
dc.creator	Donk, N.W.C.J. (Niels W.C.J.) van de	-
dc.creator	Waage, A. (Anders)	-
dc.creator	Beksac, M. (Meral)	-
dc.creator	Mellqvist, U. (Ulf)	-
dc.creator	Engelhardt, M. (Monika)	-
dc.creator	Caers, J. (Jo)	-
dc.creator	Driessen, C. (Cristoph)	-
dc.creator	Bladé, J. (Joan)	-
dc.creator	Sonneveld, P. (Pieter)	-
dc.date.accessioned	2022-11-30T08:34:19Z	-
dc.date.available	2022-11-30T08:34:19Z	-
dc.date.issued	2018	-
dc.identifier.citation	Ludwig, H. (Heinz); Delforge, M. (M.); Facon, T. (Thierry); et al. "Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network". Leukemia. 32, 2018, 1542 - 1560	es
dc.identifier.issn	0887-6924	-
dc.identifier.uri	https://hdl.handle.net/10171/64747	-
dc.description.abstract	During the last few years, several new drugs have been introduced for treatment of patients with multiple myeloma, which have significantly improved the treatment outcome. All of these novel substances differ at least in part in their mode of action from similar drugs of the same drug class, or are representatives of new drug classes, and as such present with very specific side effect profiles. In this review, we summarize these adverse events, provide information on their prevention, and give practical guidance for monitoring of patients and for management of adverse events.	es_ES
dc.language.iso	eng	es_ES
dc.publisher	Springer Nature	es_ES
dc.rights	info:eu-repo/semantics/openAccess	es_ES
dc.subject	Multiple myeloma	es_ES
dc.subject	Drugs	es_ES
dc.subject	Novel substances	es_ES
dc.title	Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network	es_ES
dc.type	info:eu-repo/semantics/article	es_ES
dc.description.note	This article is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. If you remix, transform, or build upon this article or a part thereof, you must distribute your contributions under the same license as the original. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons. org/licenses/by-nc-sa/4.0/.	es_ES
dc.identifier.doi	10.1038/s41375-018-0040-1	-
dadun.citation.endingPage	1560	es_ES
dadun.citation.publicationName	Leukemia	es_ES
dadun.citation.startingPage	1542	es_ES
dadun.citation.volume	32	es_ES